Numab Therapeutics AG is a Swiss-based biopharmaceutical company founded in 2011. The company specializes in developing multi-specific antibody-based immunotherapies for inflammation and cancer. With a proprietary platform called λ-Cap™ and MATCH™, Numab has a unique advantage in overcoming historical drug discovery barriers. Their lead candidate, NM26, targets IL-4/13 and IL-31 for best-in-class efficacy in treating atopic dermatitis and other potential indications. The company recently received a Series C investment on December 5, 2022, with HBM Healthcare Investments participating as the investor. Numab's focus on innovative therapeutic strategies and its strong investor backing positions it as a key player in the biopharma and biotechnology sectors, with potential to deliver significant patient benefits.
No recent news or press coverage available for Numab Therapeutics AG.